Company intelligence / Profile preview

Xeptiva Therapeutics

United States

Ownership: Private
Employees: ~25
Development stage: Other

Overview

Xeptiva's lead product XEP01 has completed proof-of-concept studies demonstrating safety and efficacy in improving quality of life, reducing pain, reducing medication intake, and delaying euthanasia in dogs with osteoarthritis chronic pain. The company is currently conducting pivotal controlled clinical trials for XEP01 in dogs with osteoarthritis and for XEP02 in dogs with atopic dermatitis.

Therapeutic areas: NeurologyRheumatologyDermatologyMetabolic Disorders
Modalities: Vaccine
Industry: Veterinary

Partnerships

In discussions with 4 of the 6 most important animal health biotech companies for co-development and licensing partnerships

Beyond the preview

Go deeper on Xeptiva Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xeptiva Therapeutics.

Explore the full profile